MEIP - MEI Pharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.32
+0.01 (+0.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.31
Open2.33
Bid2.29 x 1000
Ask2.65 x 1200
Day's Range2.25 - 2.39
52 Week Range1.34 - 3.26
Volume60,856
Avg. Volume213,204
Market Cap85.87M
Beta2.82
PE Ratio (TTM)33.14
EPS (TTM)0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.58
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETFs with exposure to MEI Pharma, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MEI Pharma, Inc. Here are 5 ETFs with the largest exposure to MEIP-US. Comparing the performance and risk of MEI Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017
    Capital Cube10 days ago

    MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis MEI Pharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of MEI Pharma, Inc. – Array BioPharma Inc., Curis, Inc., Celgene Corporation, XOMA Corporation, Rexahn Pharmaceuticals, Inc. and Savara, Inc. (ARRY-US, CRIS-US, CELG-US, XOMA-US, RNN-US and SVRA-US) that have ... Read more (Read more...)

  • MEI Pharma Reports First Quarter Fiscal Year 2018 Results
    PR Newswire11 days ago

    MEI Pharma Reports First Quarter Fiscal Year 2018 Results

    Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib Multiple key milestones lined up for year ahead SAN DIEGO , Nov. 8, ...

  • MEI Pharma to Present at Stifel 2017 Healthcare Conference
    PR Newswire12 days ago

    MEI Pharma to Present at Stifel 2017 Healthcare Conference

    SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 11:00 a.m. Eastern Time from the Lotte New York Palace hotel. A live webcast of the presentation can be accessed at www.meipharma.com.

  • Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
    Zackslast month

    Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session

    Aurinia Pharmaceuticals saw its shares rise nearly 8% on the day.

  • PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher
    Zacks2 months ago

    PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher

    PTC Therapeutics, Inc. (PTCT) saw its shares rise nearly 15% on the day.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MEIP earnings conference call or presentation 5-Sep-17 1:00pm GMT

    Full Year 2017 MEI Pharma Inc Earnings Call

  • GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher
    Zacks2 months ago

    GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher

    GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares rise more than 9% on the day amid huge volumes.

  • ACCESSWIRE2 months ago

    Earnings Review and Free Research Report: MEI Pharma Reported its Full Year FY17 Results

    LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on MEI Pharma, Inc. (NASDAQ: MEIP ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=MEIP ...

  • PR Newswire2 months ago

    MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference

    SAN DIEGO, Sept. 19, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 3:25 p.m. Eastern time from the InterContinental New York Barclay Hotel. A live webcast of the presentation can be accessed at www.meipharma.com.

  • ACCESSWIRE2 months ago

    Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients

    Research Desk Line-up: MEI Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Teva ...

  • Zogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2%
    Zacks2 months ago

    Zogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2%

    Zogenix, Inc. (ZGNX) was a big mover last session, as the company saw its shares rise over 5% on the day.

  • MEI Pharma-Presage Biosciences on License Deal for Voruciclib
    Zacks2 months ago

    MEI Pharma-Presage Biosciences on License Deal for Voruciclib

    MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.

  • PR Newswire2 months ago

    MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor

    SAN DIEGO and SEATTLE, Sept. 5, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib, a clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor. Under the terms of the agreement, MEI Pharma receives exclusive worldwide rights to develop, manufacture and commercialize voruciclib.

  • MEI Pharma Reports Fiscal Year 2017 Results
    PR Newswire2 months ago

    MEI Pharma Reports Fiscal Year 2017 Results

    Company Begins New Fiscal Year with $53.6 Million in Cash Clinical Progress Highlighted by Initiation of Pivotal Study for Pracinostat, Emerging Response and Safety Data for ME-401 Management Team to Host ...

  • MEI Pharma to Present at Two Upcoming Investor Conferences
    PR Newswire3 months ago

    MEI Pharma to Present at Two Upcoming Investor Conferences

    Live Webcasts from Boston on September 7th and New York on September 8th SAN DIEGO , Aug. 31, 2017 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development ...

  • MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017
    PR Newswire3 months ago

    MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017

    SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it will host a conference call with simultaneous webcast on Tuesday, September 5, 2017, at 9:00 a.m. Eastern time to discuss the Company's fiscal year 2017 results. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed AML who are unfit for intensive chemotherapy.

  • PR Newswire4 months ago

    Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

    LUGANO, Switzerland and SAN DIEGO, Aug. 2, 2017 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the first patient has been dosed in the pivotal Phase 3 study of the investigational agent pracinostat in combination with azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who are unfit to receive intensive induction chemotherapy. The randomized, double-blind, placebo-controlled study will enroll approximately 500 eligible patients worldwide.

  • Zacks4 months ago

    MEI Pharma (MEIP) Worth a Look: Stock Rises 12% in Session

    MEI Pharma, Inc. (MEIP) shares rose over 12% in the last trading session.

  • BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
    Zacks5 months ago

    BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

    BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

  • Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
    Zacks5 months ago

    Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA

    Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.

  • Shire (SHPG) Receives MAA Validation for Veyvondi by EMA
    Zacks5 months ago

    Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

    Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.

  • Indivor's Opioid Use Disorder Drug Meets Primary Endpoint
    Zacks5 months ago

    Indivor's Opioid Use Disorder Drug Meets Primary Endpoint

    Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.

  • Horizon Pharma Gets Health Canada Approval for Procysbi
    Zacks5 months ago

    Horizon Pharma Gets Health Canada Approval for Procysbi

    Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.

  • Seattle Genetics Halts Phase III Study on Leukemia Drug
    Zacks5 months ago

    Seattle Genetics Halts Phase III Study on Leukemia Drug

    Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.